Avandia Stays On Market With Increased Boxed Warning While Safety Assessed
Nov 18th 2007Drug InformationDiabetes
The US Food and Drug Administration (FDA) has asked the manufacturer of diabetes type 2 drug Avandia (rosiglitazone maleate) to carry out a new long term study to assess the cardiovascular risk of the drug. In the meantime it will stay on the market but carry a higher level of boxed warning about potential increased risk of heart attacks, said the agency in a statement on 14th November. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
